Chronic Hand Eczema

3. Top country involved in the DELTA trials besides the U.S.
4. Delgocitinib inhibits how many JAK isoforms?
7. This clinical trial assessed long-term safety and efficacy of delgocitinib.
9. This condition is characterized by relapsing or persistent hand eczema for more than 3 months.
10. This dermatologist called delgocitinib “a first-in-class topical therapy poised to simplify our approach to CHE.”
13. Brand name of delgocitinib cream approved for CHE in 2025.
15. According to Gooderham et al. 2025, what was the most common non-infectious adverse event reported during DELTA 3?

1. Trial design type for DELTA 3.
2. This JAK inhibitor is the first topical treatment FDA-approved for CHE.
5. Patients with which two IGA-CHE scores were not treated during DELTA 3 unless relapse occurred? (Answer format: “__ or __”)
6. The severity of CHE was assessed using this index.
8. First region outside the US where delgocitinib was approved.
11. Delgocitinib cream is applied how many times per day?
12. The 2025 medical meeting where post hoc data on delgocitinib was presented.
14. This symptom, alongside pain, was significantly reduced by delgocitinib.
16. This metric measured treatment success in the DELTA trials.